Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A

Kidney International

Volumn 57, Issue 1, 2000, Pages 224-231

  Binet, Isabelle ^a,b   Wallnöfer, Andreas ^a   Weber, Cornelia ^a   Jones, Richard ^a   Thiel, Gilbert ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Endothelin receptor agonist; Hypoperfusion; Nephrotoxicity; Renal plasma flow; Vasoconstriction

Indexed keywords

BOSENTAN; CYCLOSPORIN A; ENDOTHELIN; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR AGONIST;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG POTENTIATION; GLOMERULUS FILTRATION RATE; HEADACHE; HUMAN; HUMAN EXPERIMENT; KIDNEY BLOOD FLOW; KIDNEY PERFUSION; KIDNEY PLASMA FLOW; MALE; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASOCONSTRICTION; VOMITING;

EID: 0033997593     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00838.x     Document Type: Article

References (25)

1. 1. Marsen TA, Schramek H, Dunn MJ: Renal actions of endothelin: Linking cellular signaling pathways to kidney disease. Kidney Int 45:336-344, 1994
2. 2. Meyer-Lehnert H, Bokemeyer D, Friedrichs U, Backer A, Kramer HJ: Cellular mechanisms of cyclosporine side-effects: Role of endothelin. Kidney Int 52:S27-S31, 1997
3. 3. Takeda Y, Itoh Y, Yoneda T, Miyamori I, Takeda R: Cyclosporine A induces endothelin-1 release from cultured rat vascular smooth muscle cells. Eur J Pharmacol 233:299-301, 1993
4. 4. Bunchmann TE, Brookshire CA: Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells. J Clin Invest 88:310-314, 1991
5. 5. Ong ACM, Jowett TP, Scoble JE, O'Shea JA, Varghese Z, Moorhead JF: Effect of cyclosporine A on endothelin synthesis by cultured human renal cortical epithelial cells. Nephrol Dial Transplant 8:748-753, 1993
6. 6. Kon V, Sugiura M, Inagami T, Harvie BR, Ichikawa I, Hoover RL: Role of endothelin in cyclosporine-induced glomerular dys-function. Kidney Int 37:487-491, 1990
7. 7. Perico N, Dadan J, Remuzzi G: Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat. J Am Soc Nephrol 1:76-83, 1990
8. 8. Fogo A, Hellings SE, Ianagami T, Kon V: Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicity. Kidney Int 42:770-774, 1992
9. 9. Rabelink TJ, Kaasjager KAH, Boer P, Stroes EG, Braam B, Koomans HA: Effects of endothelin-1 on renal function in humans: Implications for physiology and pathophysiology. Kidney Int 46:376-381, 1994
10. 10. Kaasjager KAH, Shaw S, Koomans HA, Rabelink TJ: Role of endothelin receptor subtypes in the systemic and renal responses to endothelin-1 in humans. J Am Soc Nephrol 8:32-39, 1997
11. 11. Weber C, Schmitt R, Bimboeck H, Hopfgartner G, Van Marle SP, Peeters PAM, Jinkman HG, Jones CR: Pharmacokinetics and pharamcodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 60:124-137, 1996
12. 12. Sturrock NDC, Lang CC, MacFarlane LJ, Dockrell MEC, Ryan M, Webb DJ, Struthers AD: Serial changes in blood pressure, renal function, endothelin and lipoprotein(a) during the first 9 days of cyclosporine therapy in males. J Hypertens 13:667-673, 1995
13. 13. Perico N, Ruggenenti P, Gasparai F, Mosconi L, Benigni A, Amuchastegui CS, Gasparini F, Remuzzi G: Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. Transplantation 54:56-60, 1992
14. 14. Kohan DE: Endothelins in the normal and diseased kidney. Am J Kidney Dis 29:2-26, 1997
15. 15. Hunley TE, Fogo A, Iwasaki S, Kon V: Endothelin A receptor antagonist mediates functional but not structural damage in chronic cyclosporine nephrotoxicity. J Am Soc Nephrol 5:1718-1723, 1995
16. 16. Lanese DM, Conger JD: Effects of endothelin receptor antagonists on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest 91:2144-2149, 1993
17. 17. Benigni A, Remuzzi G: Endothelin receptor antagonists: Which are the therapeutic perspectives in renal diseases? Nephrol Dial Transplant 13:5-7, 1998
18. 18. Iwasaki S, Homma T, Kon V: Site specific regulation in the kidney of endothelin and its receptor subtypes by cyclosporine. Kidney Int 45:592-597, 1994
19. 19. Haynes WG, Webb DJ: Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 344:852-854, 1994
20. 20. Krum HMB, Viskoper RJ, Lacourciere Y, Budde M, Charlon V, Bosentan Investigators: The effect of an endothelin receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med 338:784-790, 1998
21. 21. Bartolomeusz B, Hardy KJ, Nelson AS, Phillips PA: Bosentan ameliorates cyclosporine A induced hypertension in rats and primates. Hypertension 27:1341-1345, 1996
22. 22. Remuzzi G, Benigni A: Endothelins in the control of cardiovascular and renal function. Lancet 342:589-593, 1993
23. 23. Nambi P, Pullen M, Contino LC, Brooks DP: Upregulation of renal endothelin receptors in rats with cyclosporine A-induced nephrotoxicity. Eur J Pharmacol 187:113-116, 1990
24. 24. Clozel M, Bren V, Gray GA, Kalina B, Löffler BM, Burri K, Cassal JM, Hirth GM, Müller M: Pharamacokinetical characterization of Bosentan, a new potent orally active non-peptide endothelin receptor antagonist. J Pharmacol Exp Ther 270:228-235, 1994
25. 25. Benigni A, Zoja C, Corna D, Orisio S, Facchinetti D, Benatti L, Remuzzi G: Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney. Am J Kidney Dis 27:416-423, 1996